Amicus Therapeutics (NASDAQ: FOLD) and Impax Laboratories (NASDAQ:IPXL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.

Valuation & Earnings

This table compares Amicus Therapeutics and Impax Laboratories’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Amicus Therapeutics $16.28 million 126.46 -$186.93 million ($1.47) -8.51
Impax Laboratories $812.82 million 1.69 $144.42 million ($8.07) -2.29

Impax Laboratories has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Impax Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Amicus Therapeutics and Impax Laboratories, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amicus Therapeutics 0 0 6 0 3.00
Impax Laboratories 1 9 3 0 2.15

Amicus Therapeutics presently has a consensus price target of $14.58, indicating a potential upside of 16.57%. Impax Laboratories has a consensus price target of $18.77, indicating a potential upside of 1.73%. Given Amicus Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Amicus Therapeutics is more favorable than Impax Laboratories.

Profitability

This table compares Amicus Therapeutics and Impax Laboratories’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amicus Therapeutics -1,279.88% -61.25% -20.08%
Impax Laboratories -71.08% 9.05% 3.20%

Insider & Institutional Ownership

83.6% of Impax Laboratories shares are owned by institutional investors. 3.4% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Impax Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Amicus Therapeutics has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Impax Laboratories has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

Summary

Amicus Therapeutics beats Impax Laboratories on 7 of the 13 factors compared between the two stocks.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.

Impax Laboratories Company Profile

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.